Canaccord Genuity Maintains Buy on Inari Medical, Raises Price Target to $74
Canaccord Genuity Maintains Buy on Inari Medical, Raises Price Target to $74
Canaccord Genuity維持對inari medical的買入評級,將目標股價上調至74美元
Canaccord Genuity analyst William Plovanic maintains Inari Medical (NASDAQ:NARI) with a Buy and raises the price target from $71 to $74.
Canaccord Genuity的分析師William Plovanic維持買入評級,並將inari medical(納斯達克股票代碼:NARI)的目標股價從71美元上調至74美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。